Phuturdex › Diseases › Hyperlipoproteinemia
Drugs in development · updated 30 October 2026
Hyperlipoproteinemia: drugs in development
As of 30 October 2026 there are 3 active clinical trials (recruiting or ongoing, phases I–III) on 3 drugs for hyperlipoproteinemia. 3 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Pelacarsen | III | 1 | NCT05900141 |
| Zodasiran | III | 1 | NCT07473843 |
| SRSD216 | I–II | 1 | NCT07172646 |
Sorted by most advanced phase and number of active trials.
All 3 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Hyperlipoproteinemia Type II 12 drugs
- Homozygous familial hypercholesterolemia 7 drugs
- Hypercholesterolemia 21 drugs
- Dyslipidemia 35 drugs
- Hyperlipidemia 26 drugs
- Cardiovascular disease 71 drugs
- Heart failure 104 drugs
- Aortic valve stenosis 13 drugs
- Metabolic disease 30 drugs
- Hypertriglyceridemia 18 drugs
- Pancreatitis 15 drugs
- Coronary artery disease 34 drugs
Broader categories
- Metabolic disease 30 drugs
- Nutritional and metabolic diseases 5 drugs
- Dyslipidemia 35 drugs
- Lipid metabolism disorder 4 drugs
- Hyperlipidemia 26 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D006951 “Hyperlipoproteinemias”.